Design and evaluation of extemporaneous formulations for treating pulmonary hypertension in children

چکیده

Introduction: Children, being the most vulnerable group, whose health status require urgent attention, are
constantly in need of extemporaneous formulations for the treatment of several clinical conditions, such
as pulmonary hypertension (PH)
Method: Amiloride hydrochloride/Hydrochlorothiazide (AH) combination, (1mg/10mg)/mL, and
furosemide, 1mg/mL, were separately formulated into liquid dosage forms using simple syrup BPC,
commercially available ascorbic acid syrup, deionized water and deionized water: propylene glycol
(ratios 75:25, 65:35 and 50:50) as solvents. The formulations were analyzed for stability over a 7-day
period at different storage conditions (27±2ºC protected from and exposed to sunlight, and refrigeration at
4±1ºC) using physical parameters, pH analysis, UV spectrophotometric assay and microbial count as
assessment parameters.
Results: Significant changes were observed for formulations exposed to sunlight (27º±2ºC), while
refrigerated formulations were the most stable to physical changes, but had increased viscosity. All
formulations had reduction in pH values, however, formulations containing deionized water and
propylene glycol were the most significant, with formulations protected from light at 27º±2ºC providing
the least pH changes. Refrigerated formulations retained higher medicament percentages within official
limits, while formulations exposed to light (27º±2ºC) had the highest loss of potency. Virtually all the
formulations prepared with simple syrup BPC aided growth of lactose fermenters. Refrigerated
formulations resisted microbial growth most. In terms of stability, the storage conditions can be ranked as 40±10C >
270±20C protected from light > 270±20C exposed to light.
Conclusion: The refrigerated extemporaneous formulations were the most physically stable. Deionized
water: propylene glycol (75:25) is the most appropriate solvent for formulating the formulations and
should be used only for a maximum of 6 days. It is recommended that extemporaneous formulations
containing Amiloride hydrochloride-Hydrochlorothiazide (AH) combination or furosemide are preferably
stored at 4º±1ºC protected from light, as this offers good resistance to microbial growth.
Keywords: Extemporaneous preparations, Children, Amiloride hydrochloride-Hydrochlorothiazide
combination, frusemide, storage conditions.
Résumé
Introduction : Les enfants, qui constituent le groupe le plus vulnérable et dont l’état de santé appelle une
attention urgente, ont constamment besoin de formulations extemporanées pour le traitement de plusieurs
affections cliniques telles que l’hypertension artérielle pulmonaire.
Méthode : Une combinaison d’hydro-chlorure d’amiloride et d’hydrochlorothiazide (AH) (1 mg / 10 mg) /
mL et de furosémide, 1 mg / mL, a été formulée séparément dans des formes posologiques liquides en
utilisant du sirop simple BPC, du sirop d’acide ascorbique disponible commercialement, et de l’eau
désionisée : propylène glycol (rapports 75 : 25 ; 65 : 35 et 50 : 50) en tant que solvants. La stabilité des
formulations a été analysée sur une période de 7 jours dans différentes conditions de stockage (27 ± 2 ° C
protégés et exposés au soleil, et réfrigération à 4 ± 1 ° C) en utilisant des paramètres physiques, une
analyse du pH, un dosage spectrophotométrique UV et une numération microbienne comme paramètres
d’évaluation.
Résultats : Des changements significatifs ont été observés pour les formulations exposées à la lumière
solaire (27 ° ± 2 ° C), alors que les formulations réfrigérées étaient les plus stables aux changements
physiques, mais avaient une viscosité accrue. Toutes les formulations présentaient des valeurs de pH
réduites. Cependant, les formulations contenant de l’eau désionisée et du propylène glycol étaient les plus
significatives, les formulations protégées de la lumière à 27 ºC ± 2 ºC fournissant le moins de
changements de pH. Les formulations réfrigérées conservaient des pourcentages de médicament plus
élevés dans les limites officielles, tandis que les formulations exposées à la lumière (27 ° ± 2 ° C)
présentaient la perte de puissance la plus élevée. Pratiquement toutes les formulations préparées avec du
sirop simple BPC ont contribué à la croissance des fermenteurs de lactose. Les formulations
réfrigérées ont le plus résisté à la croissance microbienne. En termes de stabilité, les conditions de
stockage peuvent être classées de 4 0± 10C> 27 0± 2 0C à l’abri de la lumière> 27 0 ± 2 0C exposées à la lumière.
Conclusion : Les formulations réfrigérées extemporanées étaient les plus stables physiquement. Eau désionisée : propylène glycol (75 : 25) est le solvant le plus approprié pour la formulation des formulations et ne doit être utilisé que pendant 6 jours au maximum. Il est recommandé de conserver les formulations extemporanées contenant une association de chlorhydrate d’amiloride et d’hydrochlorothiazide (AH) ou du furosémide à une température de 4 ± 1 ºC, à l’abri de la lumière, comme ceci offre une bonne résistance à la croissance microbienne.
Mots-clés : Préparations extemporanées, enfants, combinaison d’hydro-chlorure d’amiloride et d’hydrochlorothiazide, furosémide, conditions de stockage.
Correspondence: Dr. O.A. Adetunji, Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy,
University of Ibadan, Ibadan, Nigeria. E-mail: adetunjioladapo@gmail.com.

pdf (انگلیسی)

مراجع

Handbook of Extemporaneous Preparations. https://www.pharmpress.com/files/docs/HandbookExtemporaneousPreparation_Sample.pdf; 2016, Assessed on 23 July, 2018.

BNF for Children: Supply of Medicines In: British National Formulary for Children. British Medical Association, Royal Pharmaceutical Society of Great Britain and College of Paediatrics Royal (Ed), 2007. pp 8.

Giacoia GP, Taylor-Zapata P and Mattison D. Need for Appropriate Formulations for Children. Int J Pharm Compd, 2007, 11 (1), 5-9.

Coelho HLL, Rey LC, Medeiros MSG, et al. A critical comparison between the World Health Organization list of essential medicines for children and the Brazilian list of essential medicines. J Pediatr 2013, 89: 171-178.

Patel VP, Desai TR, Chavda BG and Katira RM. Extemporaneous dosage form for oral liquids. Pharmacophore, 2011, 2: 86-103.

Turner S, Gill A, Nunn T, Hewitt B and Choonara I. Use of “off-label” and unlicensed drugs in paediatric intensive care unit. Lancet, 1996, 347: 549-501.

Kairuz TE, Gargiulo D, Bunt C and Garg S. Quality, safety and efficacy in the ‘off-label’ use of medicines. Curr Drug Saf J, 2007, 2: 89-95.

Steinhorn, RH. Neonatal pulmonary hypertension. J Pediatr Crit Care Med, 2010, 11(2): 79–84.

Rajakopal, H, Karnik R and Sahulee R. Paediatric pulmonary hypertension. J Paed Rev, 2016, 37:3

Empar L, Renata C, Kennedy C et al. Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hyp , 2009, 27:1719–1742.

Harman J, Walker ER, Charbonneu V and Akylbekova EL. Treatment of hypertension among African Americans: the Jackson Heart Study. J Cli Hyp, 2013, 15:6, 367-374.

Bakare, OQ., Akinyinka, MR, Goodman O, et al. Antihypertensive use, prescription patterns, and cost of medications in a Teaching Hospital in Lagos, Nigeria. Nig J Cli Pract, 2016,19 (5): 668-672

Abdelaleem EA , Naguib IA, Zaazaa HE and Draz ME. Spectrophotometric methods for quantitative determination of binary mixture of hydrochlorothiazide and amiloride hydrochloride without prior separation. As J Biom Pharm Sc, 2014, 4(34), 27-33.

Naveed S, Qamar F and Zainab S. Simple UV spectrophotometric assay of Furosemide. J Inn Pharm Bio Sc, 2014,1 (3): 97-101.

Tucker IG, Geddes JA and Stewart PJ. Dose variations from an extemporaneously prepared chlorothiazide suspension. Aust J Hosp Pharm, 2010, 92: 59-63.

Taketomo CK, Chu SA, Cheng MH and Corpuz RP. Stability of captopril in powder papers under three storage conditions. Am J Hosp Pharm, 2011, 97: 1799-1801.

Alexander KS, Haribhakti RP and Parker GA. Stability of acetazolamide in suspension compounded from tablets. Am J Hosp Pharm, 2012,101: 1241-1244.

Nalawade TM, Bhat K and Sogi SHP. Bactericidal activity of propylene glycol, glycerine, polyethylene glycol 400, and polyethylene glycol 1000 against selected microorganisms. J Int Soc Prev Comm Dent, 2015, 5: 114-119.

Connors KA, Amidon GL and Stella VJ. In Connors KA, Amidon GL and Stella VJ (Eds) Chemical Stability of Pharmaceuticals. John Wiley Publishing House, New York, 1986

Costello I, Long PF, Wong IK, Tuleu C and Yeung V. Paediatric drug handling. Pharmaceutical Press, Cornwall, 2007.

Florence AT and Attwood D. In: Physicochemical principles of pharmacy. Florence AT and Attwood D (Eds). Pharmaceutical Press, London, 2006, 4th ed, pp 93–138.

Allen LV. In: The art, science, and technology of pharmaceutical compounding.. American Pharmaceutical Association (2nd ed) Washington DC, 2002.

Barnes AR. Product stability and stability testing. In: Aulton’s Pharmaceutics, The design and manufacture of medicines, Aulton ME (Ed), Churchill Livingstone Elsevier, Hungary, 2007, 3rd ed, pp 650–665,.

Glass BD and Haywood A. Stability considerations in liquid dosage forms extemporaneously prepared from commercially available products. J Pharm Pharm Sc, 2006, 9: 398–426.